230 related articles for article (PubMed ID: 27801734)
1. PD-L1 Expression in Carcinosarcomas of the Gynecologic Tract: A Potentially Actionable Biomarker.
Pinto A; Mackrides N; Nadji M
Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):393-397. PubMed ID: 27801734
[TBL] [Abstract][Full Text] [Related]
2. Uterine Carcinosarcomas: Clinical, Histopathologic and Immunohistochemical Characteristics.
Chen X; Arend R; Hamele-Bena D; Tergas AI; Hawver M; Tong GX; Wright TC; Wright JD
Int J Gynecol Pathol; 2017 Sep; 36(5):412-419. PubMed ID: 28700424
[TBL] [Abstract][Full Text] [Related]
3. CD34 immunohistochemistry in female genital tract carcinosarcoma (malignant mixed müllerian tumors) supports a dominant role of the carcinomatous component.
Costa MJ; Guinee D
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):293-9. PubMed ID: 11127921
[TBL] [Abstract][Full Text] [Related]
4. Uterine Carcinosarcomas - Diagnosis and Management.
Denschlag D; Ulrich UA
Oncol Res Treat; 2018; 41(11):675-679. PubMed ID: 30317231
[TBL] [Abstract][Full Text] [Related]
5. Landscape of Immune Checkpoint Inhibition in Carcinosarcoma (MMMT): Analysis of IDO-1, PD-L1 and PD-1.
Hacking S; Chavarria H; Jin C; Perry A; Nasim M
Pathol Res Pract; 2020 Apr; 216(4):152847. PubMed ID: 32085927
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in uterine carcinosarcoma.
Kucukgoz Gulec U; Kilic Bagir E; Paydas S; Guzel AB; Gumurdulu D; Vardar MA
Eur J Obstet Gynecol Reprod Biol; 2020 Jan; 244():51-55. PubMed ID: 31739121
[TBL] [Abstract][Full Text] [Related]
7. An immunohistochemical analysis of CD3, PD-L1, and CTLA-4 expression in carcinosarcomas of the gynecological tract and their metastases.
Karpathiou G; Chauleur C; Dal Col P; Dridi M; Hathroubi S; Mobarki M; Peoc'h M
Pathol Res Pract; 2020 Aug; 216(8):153028. PubMed ID: 32703493
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 and Mismatch Repair Status in Uterine Carcinosarcomas.
Jenkins TM; Cantrell LA; Stoler MH; Mills AM
Int J Gynecol Pathol; 2021 Nov; 40(6):563-574. PubMed ID: 33323859
[TBL] [Abstract][Full Text] [Related]
9. GHRH Receptor Expression in Malignant Mixed Müllerian Tumors: A Potentially Targetable Biopredictor.
Mackrides N; Ganjei-Azar P; Perez R; Cui T; Block N; Schally AV; Nadji M
Int J Gynecol Pathol; 2016 Mar; 35(2):142-6. PubMed ID: 26535981
[TBL] [Abstract][Full Text] [Related]
10. Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics.
Kernochan LE; Garcia RL
J Natl Compr Canc Netw; 2009 May; 7(5):550-6; quiz 557. PubMed ID: 19460280
[TBL] [Abstract][Full Text] [Related]
11. Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients.
Wyss J; Dislich B; Koelzer VH; Galván JA; Dawson H; Hädrich M; Inderbitzin D; Lugli A; Zlobec I; Berger MD
Clin Colorectal Cancer; 2019 Mar; 18(1):e20-e38. PubMed ID: 30389315
[TBL] [Abstract][Full Text] [Related]
12. Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases.
Manson QF; Schrijver WAME; Ter Hoeve ND; Moelans CB; van Diest PJ
Clin Exp Metastasis; 2019 Feb; 36(1):29-37. PubMed ID: 30547271
[TBL] [Abstract][Full Text] [Related]
13. Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors.
Takamori S; Takada K; Tagawa T; Toyokawa G; Hirai F; Yamashita N; Okamoto T; Oki E; Yoshizumi T; Oda Y; Maehara Y
Surg Oncol; 2018 Dec; 27(4):637-641. PubMed ID: 30449485
[TBL] [Abstract][Full Text] [Related]
14. Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.
Mansour MSI; Seidal T; Mager U; Baigi A; Dobra K; Dejmek A
Cancer Cytopathol; 2017 Dec; 125(12):908-917. PubMed ID: 28922567
[TBL] [Abstract][Full Text] [Related]
15. PAX8 expression in uterine malignant mesodermal mixed tumor (carcinosarcoma).
Holmes BJ; Gown AM; Vang R; Ronnett BM; Yemelyanova A
Int J Gynecol Pathol; 2014 Jul; 33(4):425-31. PubMed ID: 24901404
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
17. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 Expression Predicts a Distinct Prognosis in Krukenberg Tumor with Corresponding Origins.
Tai H; Yang Q; Wu Z; Sun S; Cao R; Xi Y; Zhao R; Zhang M; Zhang Z; Xu C
J Immunol Res; 2018; 2018():9485285. PubMed ID: 29854854
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
20. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.
Uruga H; Bozkurtlar E; Huynh TG; Muzikansky A; Goto Y; Gomez-Caraballo M; Hata AN; Gainor JF; Mark EJ; Engelman JA; Lanuti MD; Mino-Kenudson M
J Thorac Oncol; 2017 Mar; 12(3):458-466. PubMed ID: 27815126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
